Contact-2: Cabozantinib And Atezolizumab In Mcrpc

CONTACT-2: cabozantinib and atezolizumab in mCRPC

Cabozantinib in combination with atezolizumab in patients with mCRPC

Dr. Agarwal on Data With Cabozantinib/Atezolizumab in mCRPC

Bradley McGregor, MD, shares presented data investigating atezolizumab and cabozantinib in mCRPC

ASCO GU24 special: Dr. Kim Chi discusses CONTACT-2 results

European Association of Urology

Dr. Agarwal on the Safety of Cabozantinib/Atezolizumab in mCRPC

Cabozantinib With Atezolizumab for mCRPC

Oliver Sartor, MD, elaborates on presented data investigating atezolizumab and cabozantinib in mCRPC

Dr. Agarwal on Developing Biomarkers of Response to Cabozantinib/Atezolizumab in mCRPC

Tom Beer, MD on the data presented at ASCO GU20 investigating atezolizumab and cabozantinib in mCRPC

PAPMET2: cabozantinib with or without atezolizumab in PRCC

ASCO GU 2024 highlights: BRCAAway, CONTACT-2 and KEYNOTE-564

Rana McKay, MD, elaborates on presented data investigating atezolizumab and cabozantinib in mCRPC

CONTACT-303: primary PFS analysis of atezolizumab and cabozantinib in ccRCC

Disease Control With Cabozantinib Plus Atezolizumab in CRPC - Medpage Today

TALAPRO-2 Study Design for 1L in mCRPC Patients - NOW FDA Approved | #oncology #cancer #2023

OncBrothers: Practice-Changing Cancer Discussions

Dr. Pal on the Rationale for Adding Cabozantinib to Atezolizumab in Prostate Cancer

Tanya Dorff, MD, elaborates on data investigating atezolizumab and cabozantinib in prostate cancer

Cabozantinib Plus Atezolizumab for Patients With Metastatic Castration-Resistant Prostate Cancer

Daniel Petrylak, MD, on investigating atezolizumab and cabozantinib relating to prostate cancer